Drug Profile
Research programme: submicron NSAIDs - Iroko Pharmaceuticals
Alternative Names: IP-NCB; IP-NIB; IP-NINLatest Information Update: 27 Apr 2023
Price :
$50
*
At a glance
- Originator iCeutica
- Developer Iroko Pharmaceuticals
- Class Nonsteroidal anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Musculoskeletal pain
Most Recent Events
- 27 Apr 2023 Discontinued - Preclinical for Musculoskeletal pain in USA (PO)
- 28 Oct 2018 No recent reports of development identified for preclinical development in Musculoskeletal-pain in USA (PO, Controlled release)
- 28 Sep 2014 Preclinical trials in Musculoskeletal pain in USA (PO) prior to September 2014